Trial Profile

A triplet pivotal 2/3 study of TUS/VEN/HMA in acute myeloid leukemia (AML)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 21 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Tuspetinib (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Registrational; Therapeutic Use

Most Recent Events

13 Aug 2025 According to an Aptose Biosciences media release, selected TUS dose for TUS+VEN+HMA triplet phase 2/3 PIVOTAL trial.
08 Nov 2024 According to an Aptose Biosciences media release, the company prepare for Ph 2 portion of Ph 2 / Ph 3 pivotal program and present this study details at 2025: ASH.
31 Mar 2024 According to an Aptose Biosciences media release, the company plans to initiate this trial in second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com